The BioHub - by Avetix

In this episode of The BioHub Podcast, Amber is joined by Jason Silvers, President & CFO at Generate:Biomedicines, and Laurie Lee, CMO for Immunology & Inflammation. Following Generate’s recent IPO, the conversation explores what it actually looks like to scale an AI-native biotech into late-stage clinical development. Amber, Jason, and Laurie discuss GB-0895 (anti-TSLP) and the global SOL...

In this episode of The BioHub Podcast , Max sits down with Jonathan Sadeh, EVP, Head of R&D and Chief Medical Officer at Bausch Health. Jonathan is a physician-scientist with more than 20 years of experience across global pharma, having held senior leadership roles at Bristol Myers Squibb, Sanofi, AstraZeneca, and Schering-Plough. In this conversation, we discuss his journey through big pharma...

In this episode of The BioHub Podcast, Ben is joined by Craig Thompson, CEO of Cerevance. Craig has spent over three decades across biotech and pharma, leading companies through major stages of growth, development and strategic transformation. Today, he leads Cerevance, a clinical-stage neuroscience company focused on developing new medicines for neurological and neuropsychiatric diseases. In this...

In this episode of The BioHub Podcast , Max sits down with Amin Zargar, CEO of ResVita Bio, and Chad Miller, the company’s Chief Technology Officer. ResVita is developing a new class of treatments for skin diseases using engineered bacteria to deliver continuous protein therapy directly on the skin — an approach designed to transform how chronic dermatological conditions are treated. Amin brings d...

Today, we’re joined by two leaders at nChroma Bio, a company working to redefine the future of genetic medicine through epigenetic engineering and next-generation targeted delivery technologies. Melissa Bonner, Chief Scientific Officer, and Dr. Jenny Marlowe, Chief Development Officer, are helping lead the development of therapies designed not just to edit genes, but to control how genes are turne...

In this episode we welcome Tom Frohlich the CEO of Jade Biosciences

Today’s guest is James Mackay, Chief Executive Officer of Crystalys — a biotech company tackling one of the most common yet often overlooked metabolic diseases: gout. James brings decades of experience across the biotechnology and pharmaceutical industries, including senior leadership roles and a track record of helping bring innovative therapies to market. His career spans global pharma and emerg...

In this episode of The BioHub Podcast by Avetix , Ben sits down with Shawn Singh, CEO of Vistagen Therapeutics, to discuss his career across biotech, venture capital, CROs, public markets, and the evolution of neuropsychiatry drug development. With more than 30 years of experience spanning private and public biotechnology, medtech, pharma, venture capital, and contract research, Shawn brings a uni...

In this episode of The BioHub Podcast, we’re joined by Karen Lewis, Chief People Officer at Cardurion Pharmaceuticals, to discuss her career journey through biotech, talent acquisition, HR leadership, public and private companies, and the realities of building culture in fast-growing organisations. Karen shares how her career began at the bench as a scientist before moving into recruitment, HR bus...

On this episode we discuss the AAVantgarde story with CEO, Natalia Misciatelli. Founded by Professor Alberto Auricchio in 2021 as a spin-out from Telethon Institute of Genetics and Medicine in Naples, we discuss their dual-vector and intein-based platforms and how the team are positioning to deliver large therapeutic genes for inherited retinal diseases. Backed by household VC names including; For...

We were delighted to welcome Ken Macnamara, an accomplished biotech executive with deep experience spanning product development, advanced therapeutics, and company leadership, onto The BioHub! Over the course of his career, Ken has held senior roles across innovative life sciences businesses, helping translate cutting-edge science into real-world therapies and scalable commercial platforms. He cur...

In this episode of The BioHub Podcast by Avetix , Ben sits down with Dr. Arun Swaminathan, CEO of Coya Therapeutics, a clinical-stage biotechnology company developing therapies designed to enhance regulatory T cell function and target systemic inflammation and neuroinflammation. Arun brings more than 20 years of healthcare leadership experience across corporate strategy, business development, oper...

In this episode of The BioHub Podcast , Max sits down with Haseeb Ahmad, CEO of Purespring Therapeutics. Haseeb brings over 25 years of experience in the life sciences industry, including leadership roles at Novartis where he oversaw a $15B business across Europe and led their gene therapies division. But this conversation goes beyond titles. Haseeb shares how his upbringing in Liverpool and the i...

Today, we’re joined by a leader working at the cutting edgeof immunology and eye disease. Elizabeth Jeffords is the CEO of Iolyx Therapeutics, a clinical-stage biotech company focused on transforming how we treat inflammatory and autoimmune diseases of the eye. Iolyx sits at the emerging intersection of immunology andophthalmology—what’s often called immuno-ophthalmology. The company is developing...

Welcome to today’s episode, where we sit down with Derek Adams, CEO of Stellular Bio. Derek has been helping steer Stellular Bio at the intersection of advanced biomanufacturing and next-generation therapeutic development—turning complex scientific challenges into real-world medical possibilities. Prior to Stellular, Derek was Chief Manufacturing and Technology Officer at bluebird bio , one of the...

In this episode of The BioHub Podcast , Max sits down with Harold Bernstein. Harold brings decades of experience across biotech and pharma, with a career spanning leadership roles, company building, and advancing innovative therapies through development. In this conversation, we explore Harold’s journey through the industry, the lessons he’s learned along the way, and his perspective on how biotec...

In this episode of the BioHub Podcast, Amber is joined by Daniel, Co-Founder and CEO of Model Medicines. Model Medicines is building an AI-driven drug discovery platform with a fundamentally different approach, focusing on applying machine learning to problems where traditional methods have failed. Daniel shares how the team is targeting biological “choke points” across multiple diseases, why thro...

We sit down with Rafiq Hasan, co-founder & CEO of Complement Therapeutics, at their London offices to unpack a milestone-loaded past 6 months. Rafiq shares the company's thesis, based on research from Manchester university, and how in practice they are targeting the complement system. We also dig into a landmark moment for the company - the recent dosing of patients in OPTI-GAIN, their Pha...

In this episode of The BioHub Podcast , Max sits down with Lu Han, CEO of Imviva Biotech. Lu’s journey spans science, venture investing, and now company building, bringing a unique perspective to one of the most competitive areas in biotech. Imviva is focused on developing off-the-shelf CAR-T therapies , aiming to make cell therapies more scalable and accessible for patients across oncology and au...

Today's guest is Dee Dragon, she sits at the interface of People Strategy at Senti Bio. She has entered the industry in the last 6+ years and has really made a difference in the culture at Senti. Not only that, she has co-founded the Biotech CHRO Sisterhood, a movement that is taking the biotech industry by storm. In this episode we explore Dee's journey and how she entered the biotech space, and...

Today’s guest sits at the intersection of cutting-edge science and bold entrepreneurship. Dr. Lan Huang is the Co-Founder, CEO, and Chairman of SEED Therapeutics, where she’s leading the charge in developing next-generation medicines through targeted protein degradation—an approach that’s redefining what’s possible in drug discovery. But she didn’t stop at the lab bench. Lan is also a seasoned bio...

In this episode of The BioHub Podcast, Amber sits down with Nazli Azimi, Co-founder and CEO of Therna Biosciences. Nazli has previously founded and scaled two biotech companies through to acquisition, and is now focused on building AI-driven platforms to design programmable RNA medicines. In this conversation, we explore why many first-generation AI drug discovery companies struggled, and why grou...

On this episode we meet Sam Possemiers, CEO at MRM Health, the leading developers of microbiome-based therapeutics within IBD. We discuss the origins of their CORAL platform, which was brought to life in the basement of Ghent University by Willy Verstraete. The concept of "Microbial Resource Management" and how Sam used the profits from his successful CRO, ProDigest, to self-fund the seed and go a...

In this episode of The BioHub Podcast , Max sits down with Dr. Atta Behfar, Co-Founder of Rion and Professor of Regenerative Medicine at Mayo Clinic. Atta’s work at Mayo led to a key discovery that became the foundation for Rion, a clinical-stage company developing exosome-based therapeutics through its Purified Exosome Product (PEP) platform. In this conversation, Atta shares the story behind tha...

In this episode of The BioHub Podcast , Max sits down with Srinivas Rao, CEO of atai Beckley. Srini has been there from the very beginning, helping build atai into one of the leading companies in the mental health and psychedelics space, and now leading the next chapter following the merger with Beckley. In this conversation, we talk about how atai was founded, the evolution of the psychedelics sp...